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Highlights
· Changes in depressive symptoms were analyzed using network analysis.
· Improvements in symptoms were largely related to subsequent improvements of other
symptoms.
· Deterioration in symptoms was associated with other symptoms’ worsening over
time.
· Sad/depressed mood, diminished interest, suicidal ideation were the most central
symptoms.




Background. Network perspective to mental disorders suggests that depression develops due
to interrelated associations between individual symptoms rather than due to a common cause.
However, it is unclear whether long-term longitudinal associations between specific
symptoms of depression demonstrate coherent patterns. We examined the temporal sequences
and changes in depressive symptoms over time, and whether some symptoms are more
central than others in inducing changes in the rest of the symptoms over time. We also
compared the network structure of depressive symptoms between people who were and were
not taking medication for depression or anxiety.
Methods. Data were from the Survey of Health, Aging and Retirement in Europe, with five
follow-ups conducted between 2004 and 2017. Participants who had data on depressive
symptoms from at least two study waves were analyzed (n=72,971). Depressive symptoms
were self-reported using the 12-item EURO-D scale.
Results. All individual symptoms were longitudinally associated with each other. Changes in
sad or depressed mood, diminished interest, and suicidal ideation were the most strongly
associated with changes in other symptoms. There were no consistent differences in symptom
associations between individuals taking versus not taking psychotropic medication.
Limitations. Depressive symptoms were self-reported and measured every two years, which
may dilute some short-term temporal sequences of the symptoms.
Conclusions. Our findings demonstrate differences between depressive symptoms in their
long-term associations with other depressive symptoms in the general population. Changes in
sad or depressed mood, diminished interest, and suicidal ideation have the strongest
associations with changes in the rest of the symptoms.




Depression includes cognitive, emotional, and somatic symptoms that can form multiple
symptom combinations in the diagnosis of clinical depression (Fried, 2017; Fried and Nesse,
2015). Recent research has challenged the idea that these depressive symptoms are
representations of an underlying disease of depression (“common cause”). Instead,
depression is suggested to develop as a result of causal interactions between symptoms rather
than as a result of underlying common cause (Borsboom, 2017; Cramer et al., 2010). A
growing number of studies have applied a network approach to assess the structure of
psychopathology and the patterns between specific symptoms of depression (for a review, see
Fried et al., 2017). The majority of previous studies have been cross-sectional but some
studies have examined longitudinal networks of depressive symptoms (Bos et al., 2017;
Bringmann et al., 2015; Groen et al., 2019) or affective states more generally (Klippel et al.,
2018; Snippe et al., 2017).
Some symptoms may be more influential than others in triggering the onset of further
symptoms (Borsboom, 2017). In general, all symptoms of depression tend to change in
unison over time, that is, improvements and deteriorations in symptoms are correlated across
individual symptoms (Bringmann et al., 2015; Groen et al., 2019). Some studies have
reported that an increase in suicidal thoughts and loss of pleasure may be particularly
strongly related to increase in other symptoms over short time periods in weekly assessments
(Bos et al., 2017; Bringmann et al., 2015). Previous studies have mainly focused on how the
presence of a specific symptom at one timepoint is related to the presence of other symptoms
at a subsequent timepoint. Less is known how a change in a specific symptom is related to
changes in all other symptoms. Moreover, most of the longitudinal studies have focused on
short-term assessments of depressive symptoms across days or weeks, and it is unknown
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whether the symptom-specific associations can be observed over longer time intervals of
several years.
The symptom associations of depression may also depend on other health-related
factors. Use of antidepressant medication is relatively common in the general population,
with on average 7.2% of Europeans using antidepressant medication (Lewer et al., 2015).
Antidepressant medication may influence specific depressive symptoms differently
(Hieronymus et al., 2016; Lisinski et al., 2020). However, it is not known whether
antidepressant medication also influences the associations between depressive symptoms
over time. Given that antidepressant medication is targeted to reduce symptoms of
depression, one could hypothesize that antidepressant medication strengthens the positive
effects of improvements between depressive symptoms and attenuates the negative effects of
deterioration between depressive symptoms.
The present study examined the long-term networks of depressive symptoms in a
large panel study that covers most European countries. The first aim was to examine the
longitudinal associations of depressive symptoms and changes (improvement or worsening)
of depressive symptoms over time. The second aim was to examine whether some symptoms
are more central than others in triggering other symptoms over the long-term course of
depression. Based on previous studies (Bos et al., 2017; Bringmann et al., 2015), we expect
that at least suicidal ideation and loss of pleasure/interest will be important symptoms in
triggering changes in other symptoms. Finally, the third aim was to compare the long-term
dynamic networks of depressive symptoms between people who used and did not use
medication for depression and anxiety. We hypothesized that taking medication would
amplify the positive associations of improvements between symptoms and attenuate the




The Survey of Health, Ageing and Retirement in Europe (SHARE) is a cross-national
panel database covering 27 European countries and Israel. It contains data on health, socio-
economic status, and social and family networks of about 140,000 persons aged 50 or older
and their spouses. To date, SHARE has collected six panel waves (Wave 1, 2, 4, 5, 6, and 7),
as well as data on retrospective life histories (SHARELIFE, Wave 3). For methodological
details on SHARE, see Börsch-Supan et al. (2013); the response or retention rates are
reported elsewhere (Bergmann et al., 2019).
In this study, we used all available data on depressive symptoms from SHARE panel
waves, which comprised five follow-ups: from wave 1 (taking place in 2004-2006) to 2
(2006-2010), 2 to 4 (2010-2012), 4 to 5 (2013), 5 to 6 (2015), and 6 to 7 (2017) (Börsch-
Supan, 2019a, 2019b, 2019c, 2019d, 2019e, 2019f). A total of 117,278 participants (263,748
total person-observations) aged 20-100 years had data on all depressive symptoms from any
of the study waves. Of those, 72,971 participants (146,470 total person-observations) had
data from at least two follow-ups and comprised the analytical sample for this study. The
results from the attrition analysis show that the participants with a higher number of
depressive symptoms were more likely to drop out during the follow-ups (OR=1.02, 95%
1.01, 1.02). The associations between the specific depressive symptoms and the loss to
follow-up are shown in Supplementary Table 1.
SHARE was reviewed and approved by the Ethics Committee of the University of
Mannheim (Waves 1–4) and by the Ethics Council of the Max Planck Society (Waves 5–7).
In addition, the country implementations of SHARE were reviewed and approved by the
respective ethics committees or institutional review boards whenever this was required.
Measures
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Depressive symptoms. Depressive symptoms were self-reported using the 12-item
EURO-D scale (Prince et al., 1999b, 1999a). The scale was originally developed to
harmonise data on late-life depression from population-based studies across European
countries (Prince et al., 1999b). The EURO-D items were originally derived from the
Geriatric Mental State scale and comprise sad or depressed mood, pessimism, suicidal
ideation, guilt, sleep, loss of interest, irritability, appetite, fatigue, concentration, enjoyment,
and tearfulness. Individual symptoms were scored as 0 (‘not present’) and 1 (‘present’)
(Prince et al., 1999b). Based on the initial validation in the cross-European study on
depression prevalence (EURODEP), the scale has an adequate internal consistency and
validity (Prince et al., 1999b, 1999a). Further studies using SHARE data support the cross-
cultural validity of the scale (Castro-Costa et al., 2008).
Medication for depression or anxiety. All survey respondents were asked whether
they were currently taking drugs at least once a week for depression or anxiety. Respondents
who reported taking medication for depression or anxiety were coded as 1 (‘treatment
group’), and those who did not report taking medication for depression or anxiety – as 0 (‘no
treatment’ group).
Control variables. We adjusted all analyses for age, sex, mean level of depression in
the country of interview, and follow-up time.
Statistical analysis
Modelling longitudinal network systems. First, we examined time-lagged
associations between depressive symptoms by conducting a model where a depressive
symptom at each time point (t) was used as a predictor of that same symptom at the
subsequent time point (t + 1; to control for possible autoregressive effects) and of all other
symptoms at the subsequent time point (t + 1). For this, separate logistic regression analyses
were performed for each symptom using the Stata logit command. We conducted all the
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analyses using the robust cluster estimator to account for the dependence of measurements
within the same individual. The analyses were adjusted for age, sex, mean level of depression
in the country of interview, and follow-up time.
We then saved the estimates from logistic regression analyses and used these
estimates as the edge weights to visualize the networks of symptoms using the qgraph
package in R. In the networks, each node represents a presence of a symptom and each edge
is the association of all symptoms at one time point with a symptom of interest at a
subsequent time point. The autoregressive associations were not shown in the networks and
also not included in the calculation of the centrality indices, since we were not interested in
showing the time-lagged associations within the same symptoms. Two centrality indices –
out-strength and in-strength – were used to examine symptoms’ centralities in the networks.
Out-strength (i.e., sum of outgoing edge weights from a specific node) indicates
how connected a symptom was at one time point to other symptoms at a subsequent time
point; in-strength (i.e., sum of ingoing edge weights to a specific node) reflects how likely a
symptom was to follow after other symptoms being present at a prior time point. Centrality
indices were visualized using ‘centralityPlot’ command in the qgraph package in R.
Modelling of change in networks. We further tested whether changes in all
depressive symptoms within each follow-up (e.g., from time 1 to time 2) were related to the
presence of each depressive symptom at the end of the follow-up (e.g., time 2) when that
symptom was present at baseline (e.g., time 1). A change score was created for each symptom
by subtracting the symptom score at time-point t from the same symptom score at time-point
t+1. We categorized the change score into (a) a score characterizing improvement of
symptoms (0 = remaining the same or worsening, 1 = improving) and (b) a score
characterizing worsening of symptoms (0 = remaining the same or improving, 1 =
worsening). We performed separate logistic regression analyses with robust cluster estimator
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for each depressive symptom at t+1 as the outcome and (a) improvement or (b) worsening of
all other symptoms from t to t+1 as the predictors when the symptom used as the outcome
was present at time t. Improvement and worsening of symptoms were analyzed in separate
models. The analyses were adjusted for age, sex, mean level of depression in the country of
interview, and follow-up time. Likewise, we used the estimates from the logistic regression
analyses as the edge weights to visualize the networks of depressive symptoms using qgraph
package, and plot the centrality indices (in-strength and out-strength) using ‘centralityPlot’
command in the qgraph package in R.
Differences in networks between ‘treatment’ and ‘no treatment’ groups. We
repeated the change models in two groups: (a) people who reported taking medication for
depression or anxiety (‘treatment’ group) and (b) those who did not report taking medication
for depression and anxiety (‘no treatment’ group). To ensure comparability between the ‘no
treatment’ group and ‘treatment’ group, we selected only those respondents in the ‘no
treatment’ group who have three or more depressive symptoms at the baseline of each
follow-up, so that the mean level of depressive symptoms became similar in both groups (M
= 4.4 in ‘treatment’ group and M = 4.5 in ‘no treatment’ group). The ‘treatment’ group
comprised 6,365 participants and the ‘no treatment’ group included 33,490 participants. We
used the centrality indices (in-strength and out-strength) to compare the networks of
depressive symptoms in these two groups. Confidence intervals for centrality indices were
calculated by resampling values for the centrality indices 500 times from a distribution which
was defined by the edge weight (distribution mean) and standard error (distribution standard
deviation) obtained from the regression analysis.
All statistical analyses were performed in Stata 15 (StataCorp, 2017) and RStudio




The mean age of participants at baseline was 63.2 (SD = 9.93), 57% were female. The
prevalence of depressive symptoms in the whole sample is shown in Table 1. The most
prevalent symptoms were being sad or depressed over the last month (38.8%), fatigue (34%),
trouble with sleep (33.8%), and irritability (27.6%).
Table 1. Frequency of depressive symptoms in the analytical sample (n=146,470 total
person-observations).
EURO-D item Frequency
Sad or depressed last month 38.8%
Hopes for the future a 15.5%
Felt would rather be dead 6.6%
Feels guilty 8.3%
Trouble sleeping 33.8%







a No hopes mentioned
b Diminution in desire for food
c Difficulty in concentrating on entertainment or reading
d Fails to mention any enjoyable activity
11
Time-lag model
Figure 1.A shows the dynamic network of depressive symptoms in the total sample
based on the time-lag model. All associations in the network were positive indicating that
presence of a symptom at one time point was related to presence (but not absence) of other
depressive symptoms at subsequent time point. Figure 1.B shows the centrality indices for the
network in the total sample. Suicidal ideation (“Felt would rather be dead”) had the highest
out-strength estimate, suggesting that suicidal ideation was most connected to other
symptoms in the network over time. Suicidal ideation, along with diminished interest and
being sad or depressed, also had the highest in-strength estimate, indicating that these
symptoms were likely to follow after the presence of other symptoms.
Change model
Figure 2.A presents the dynamic network of improvement in depressive symptoms
over time in the total sample based on the change model. Most of the associations were
negative (shown in red color) indicating that improvement in symptoms over the follow-up
was associated with subsequent absence of a symptom at the end of the follow-up when that
symptom of interest was present at the beginning of the follow-up. Sad or depressed mood
had the highest out-strength estimate, suggesting that improvement in sad or depressed mood
over the follow-up was most connected with subsequent absence of other symptoms at the
end of the follow-up (Figure 2.B). Suicidal ideation had the highest in-strength estimate,
suggesting that improvement in suicidal ideation was particularly likely to occur after
improvement in other symptoms (Figure 2.B).
Figure 3.A presents the dynamic network of deterioration of depressive symptoms
over time in the total sample based on the change model. All associations were positive (in
blue color) indicating that deterioration of symptoms over the follow-up was associated with
subsequent deterioration of other symptoms at the end of the follow-up. Suicidal ideation and
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less interest in things had the highest out-strength estimate, suggesting that deterioration in
these two symptoms over the follow-up was most connected with deterioration in all other
symptoms at the end of the follow-up (Figure 3.B). Sad or depressed mood had the highest
in-strength estimate, suggesting that deterioration in sad or depressed mood was particularly
likely to occur after deterioration of all other symptoms (Figure 3.B).
‘Treatment’ and ‘no treatment’ group
Supplementary Table 2 shows the odds ratios for the associations of medication use
for depression or anxiety and having depressive symptoms. In the cross-sectional analyses,
medication use was associated with lower probability of some depressive symptoms (e.g., sad
or depressed mood, irritability, and pessimism) and higher probability of other symptoms
(e.g., suicidal ideation, feeling guilty, and diminished interest in things). In the longitudinal
analyses, medication use was related to higher probability of all depressive symptoms.
The dynamic networks of improvement and deterioration of depressive symptoms
over time were similar between ‘treatment’ and ‘no treatment’ groups (Supplementary Figure
1-2). The centrality indices were also largely similar between the two groups (Figure 4). In
the change model for improvement of depressive symptoms, sad or depressed mood had the
highest out-strength estimates in both groups, without any difference between the ‘treatment’
and ‘no treatment’ groups (Supplementary Table 3). However, participants in ‘no treatment’
group had higher out-strength estimates for tearfulness and irritability, but lower for suicidal
ideation, as compared to ‘treatment’ group (Supplementary Table 3). Also, suicidal ideation
and diminished interest had the highest in-strength estimates for both groups, whereas sad or
depressed mood had higher in-strength and pessimism had lower in-strength in ‘no treatment’
group (Supplementary Table 3). In the change model for deterioration of depressive
symptoms, suicidal ideation and less interest in things had the highest out-strength estimates
in both groups, without any difference between the ‘treatment’ and ‘no treatment’ groups
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(Supplementary Table 4). However, sad or depressed mood had the higher in-strength
estimate in ‘treatment group’; whereas less interest in things had higher in-strength estimate
in ‘no treatment group’ (Supplementary Table 4).
Discussion
This study examined longitudinal network associations between depressive symptoms in the
general population using data from the prospective cohort study covering most European
countries. We found that all symptoms were directly or indirectly connected with each other
and that a presence of a symptom at one time point was related to higher probability of other
depressive symptoms later in time. Improvement in symptoms over time was associated with
subsequent improvement in most other symptoms, whereas worsening of symptoms over
time was related to deterioration of other symptoms over time.
We found some support for the hypothesis that some symptoms are more important
than others in the longitudinal dynamics of symptoms. The two core symptoms for
depression diagnosis – sad or depressed mood and diminished interest in things – along with
suicidal ideation were the most central symptoms in the network of changes in depressive
symptoms over time. Our findings are consistent with studies showing that depressed mood
and anhedonia are most reactive to changes in other symptoms (i.e., high in-strength
estimate), whereas suicidal ideation may induce other symptoms (i.e., high out-strength
estimate) (Bos et al., 2017; Bringmann et al., 2015; Fried et al., 2016; Hakulinen et al., 2020).
These findings are also in line with the current diagnostic approach (both ICD and DSM-V)
which regards depressed mood and anhedonia as the core symptoms for a diagnosis of
clinical depression (American Psychiatric Association, 2013; World Health Organization,
2004).
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Deterioration of sad or depressed mood was more likely to occur after deterioration of
other symptoms; whereas improvement in sad or depressed mood was more likely to trigger
improvements in other symptoms over time. Both improvement and deterioration of
diminished interest was reactive to changes in other symptoms, and deterioration of
diminished interest was also likely to induce deterioration in other symptoms over time.
Previous longitudinal studies applying a directed network analysis have also shown that
sadness and loss of interest were reactive to changes in other symptoms (Bos et al., 2017;
Bringmann et al., 2015). However, in contrast to studies by Bos et al., 2017; Bringmann et
al., 2015, absence of enjoyment did not play any central role in the symptom networks in our
sample. Further studies are needed to investigate the (strength) centrality of sad or depressed
mood and anhedonia in different samples and using different measures of depressive
symptoms.
In line with our expectations, suicidal ideation also emerged as one of the most central
symptoms in the networks of depressive symptoms. Suicidal ideation is among the strongest
predictors of a diagnosis of severe depression which requires immediate attention and
treatment (Malhi et al., 2014). We found that deterioration in suicidal ideation was most
likely to induce deterioration in other symptoms over time. This accords with studies using
directed network analyses (Bringmann et al., 2015) and direction of dependence methods
(García-Velázquez et al., 2020) which suggest that suicidality is likely to reinforce other
depressive symptoms.
It is not exactly known why and how antidepressant medication works (Harmer et al.,
2009). Previous studies have shown that antidepressant medication may influence some
symptoms differently than others (Hieronymus et al., 2016; Lisinski et al., 2020), but there
have been no studies on whether antidepressant medication influences the strength of
associations between depressive symptoms over time. We hypothesized that antidepressant
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medication might strengthen the positive effects of improvements between depressive
symptoms and attenuate the negative effects of deterioration between depressive symptoms.
We found no consistent differences in symptom networks between those taking versus not
taking psychotropic medication. Two previous studies have also reported that the dynamic
network structures of depressive symptoms (Bringmann et al., 2015) and mental states
(Snippe et al., 2017) did not differ greatly in response to psychotherapy or antidepressant
medication in small clinical trials. It should be noted, however, that the measure of
medication use for depression or anxiety might have been too broad in this study, since no
details on the type of medication, dosage, and length of use were available. It is therefore
possible that no observed differences in the networks of depressive symptoms between
‘treatment’ and ‘no treatment’ groups reflect the imprecise definition of medication use. Our
findings are based on a general population sample, and further research from clinical trials is
needed to evaluate the role of antidepressant treatment in shaping the network structure of
depressive symptoms.
Limitations
This study has some limitations which should be acknowledged. First, as with most
longitudinal data, loss to follow-up was also inevitable in this study. The attrition analysis
showed that participants reporting a higher number of depressive symptoms were more likely
to drop out; therefore, the selective attrition might have biased our findings. Second, the
measurements of depressive symptoms were conducted every two years. Depressive
symptoms can vary greatly across long time periods (Eeden et al., 2019), and this may dilute
some of the short-term temporal sequences between symptoms. However, our findings are
similar to previous studies using intensive longitudinal data across days or weeks, suggesting
that symptom-level analysis may be feasible with long-term follow-up data as well. Third,
depressive symptoms were self-reported and thus involve the risk of reporting bias. This may
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be problematic for symptom-level analysis especially if the participants are not able to
discriminate between different symptoms of depression in detail. Fourth, we did not have
details regarding the medication use, such as dosage, length of use, or treatment adherence
over time. Finally, our sample comprised people aged 50 or older which may limit the
generalizability of our findings to younger cohorts.
Conclusions
In conclusion, symptom-level analysis over several years suggested that sad or
depressed mood, diminished interest, and suicidal ideation may be the most central symptoms
in the networks for changes in depressive symptoms over time. Psychotropic medication use
did not modify these associations.
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Figure 1. (A) Dynamic network of depressive symptoms and (B) centrality indices for the
network of depressive symptoms based on the time-lag model in the total sample
(n=146,470). Positive associations are shown in blue; line (edge) thickness indicates weight.
Note. Depr: sad or depressed last month; pess: pessimism (no hopes for the future); suic: felt
would rather be dead; guil: feels guilty; slep: trouble sleeping; intr: less interest in things; irri:
irritability; appt: appetite; fatg: fatigue; conc: difficulty in concentrating on entertainment or
reading; enjy: enjoyment (fails to mention any enjoyable activity); tear: tearfulness.
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Figure 2. (A) Dynamic network of subsequent improvement in depressive symptoms and (B)
centrality indices for this network based on the change model in the total sample. Negative
associations in red indicate improvement of symptoms, and positive associations in blue –
deterioration of symptoms; line (edge) thickness indicates weight.
Note. Depr: sad or depressed last month; pess: pessimism (no hopes for the future); suic: felt
would rather be dead; guil: feels guilty; slep: trouble sleeping; intr: less interest in things; irri:
irritability; appt: appetite; fatg: fatigue; conc: difficulty in concentrating on entertainment or
reading; enjy: enjoyment (fails to mention any enjoyable activity); tear: tearfulness.
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Figure 3. (A) Dynamic network of subsequent deterioration of depressive symptoms and (B)
centrality indices for this network based on the change model in the total sample. Positive
associations in blue indicate deterioration of symptoms, and negative associations in red –
improvement of symptoms; line (edge) thickness indicates weight.
Note. Depr: sad or depressed last month; pess: pessimism (no hopes for the future); suic: felt
would rather be dead; guil: feels guilty; slep: trouble sleeping; intr: less interest in things; irri:
irritability; appt: appetite; fatg: fatigue; conc: difficulty in concentrating on entertainment or
reading; enjy: enjoyment (fails to mention any enjoyable activity); tear: tearfulness.
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Figure 4. Centrality indices for the networks of depressive symptoms in ‘treatment group’
and ‘no treatment group’ based on the change model ((A) improvement of symptoms over
time, (B) deterioration of symptoms over time).
(A Improvement (B Deterioration
